Literature DB >> 28384640

Comparative Diagnostic Accuracy of the ACE-III, MIS, MMSE, MoCA, and RUDAS for Screening of Alzheimer Disease.

Jordi A Matías-Guiu1, María Valles-Salgado, Teresa Rognoni, Frank Hamre-Gil, Teresa Moreno-Ramos, Jorge Matías-Guiu.   

Abstract

BACKGROUND: Our aim was to evaluate and compare the diagnostic properties of 5 screening tests for the diagnosis of mild Alzheimer disease (AD).
METHODS: We conducted a prospective and cross-sectional study of 92 patients with mild AD and of 68 healthy controls from our Department of Neurology. The diagnostic properties of the following tests were compared: Mini-Mental State Examination (MMSE), Addenbrooke's Cognitive Examination III (ACE-III), Memory Impairment Screen (MIS), Montreal Cognitive Assessment (MoCA), and Rowland Universal Dementia Assessment Scale (RUDAS).
RESULTS: All tests yielded high diagnostic accuracy, with the ACE-III achieving the best diagnostic properties. The area under the curve was 0.897 for the ACE-III, 0.889 for the RUDAS, 0.874 for the MMSE, 0.866 for the MIS, and 0.856 for the MoCA. The Mini-ACE score from the ACE-III showed the highest diagnostic capacity (area under the curve 0.939). Memory scores of the ACE-III and of the RUDAS showed a better diagnostic accuracy than those of the MMSE and of the MoCA. All tests, especially the ACE-III, conveyed a higher diagnostic accuracy in patients with full primary education than in the less educated group. Implementing normative data improved the diagnostic accuracy of the ACE-III but not that of the other tests.
CONCLUSIONS: The ACE-III achieved the highest diagnostic accuracy. This better discrimination was more evident in the more educated group.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Addenbrooke’s Cognitive Examination; Alzheimer disease; Memory Impairment Screen; Mini-Mental State Examination; Montreal Cognitive Assessment; Neuropsychological assessment; Rowland Universal Dementia Assessment Scale; Screening

Mesh:

Year:  2017        PMID: 28384640     DOI: 10.1159/000469658

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  14 in total

1.  High-frequency repetitive transcranial magnetic stimulation combined with cognitive training improves cognitive function and cortical metabolic ratios in Alzheimer's disease.

Authors:  Fengxia Zhang; Yuanyuan Qin; Lingfeng Xie; Caixia Zheng; Xiaolin Huang; Min Zhang
Journal:  J Neural Transm (Vienna)       Date:  2019-07-10       Impact factor: 3.575

2.  CCCDTD5 recommendations on early and timely assessment of neurocognitive disorders using cognitive, behavioral, and functional scales.

Authors:  David F Tang-Wai; Eric E Smith; Marie-Andrée Bruneau; Amer M Burhan; Atri Chatterjee; Howard Chertkow; Samira Choudhury; Ehsan Dorri; Simon Ducharme; Corinne E Fischer; Sheena Ghodasara; Nathan Herrmann; Ging-Yuek Robin Hsiung; Sanjeev Kumar; Robert Laforce; Linda Lee; Fadi Massoud; Kenneth I Shulman; Michael Stiffel; Serge Gauthier; Zahinoor Ismail
Journal:  Alzheimers Dement (N Y)       Date:  2020-11-11

3.  Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project.

Authors:  Elizabeth E Blue; Joshua C Bis; Michael O Dorschner; Debby W Tsuang; Sandra M Barral; Gary Beecham; Jennifer E Below; William S Bush; Mariusz Butkiewicz; Carlos Cruchaga; Anita DeStefano; Lindsay A Farrer; Alison Goate; Jonathan Haines; Jim Jaworski; Gyungah Jun; Brian Kunkle; Amanda Kuzma; Jenny J Lee; Kathryn L Lunetta; Yiyi Ma; Eden Martin; Adam Naj; Alejandro Q Nato; Patrick Navas; Hiep Nguyen; Christiane Reitz; Dolly Reyes; William Salerno; Gerard D Schellenberg; Sudha Seshadri; Harkirat Sohi; Timothy A Thornton; Otto Valadares; Cornelia van Duijn; Badri N Vardarajan; Li-San Wang; Eric Boerwinkle; Josée Dupuis; Margaret A Pericak-Vance; Richard Mayeux; Ellen M Wijsman
Journal:  Dement Geriatr Cogn Disord       Date:  2018-02-27       Impact factor: 2.959

4.  Evaluating Residual Cognition in Advanced Cognitive Impairment: The Residual Cognition Assessment.

Authors:  Alex Soli; Giacomina Savoldelli; Angelica Rota; Sara Zonca; Gloria Belotti; Fabrizio Lazzarini
Journal:  Dement Geriatr Cogn Disord       Date:  2021-12-08       Impact factor: 2.959

5.  One Size Does Not Fit All: Comparative Diagnostic Accuracy of the Rowland Universal Dementia Assessment Scale and the Mini Mental State Examination in a Memory Clinic Population with Very Low Education.

Authors:  Miriam Goudsmit; Jos van Campen; Thelma Schilt; Chris Hinnen; Sanne Franzen; Ben Schmand
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2018-08-29

Review 6.  Addenbrooke's cognitive examination III in the diagnosis of dementia: a critical review.

Authors:  Diana Bruno; Sofia Schurmann Vignaga
Journal:  Neuropsychiatr Dis Treat       Date:  2019-02-15       Impact factor: 2.570

7.  Comparative diagnostic accuracy of ACE-III and MoCA for detecting mild cognitive impairment.

Authors:  Bian-Rong Wang; Hui-Fen Zheng; Chang Xu; Yi Sun; Ying-Dong Zhang; Jian-Quan Shi
Journal:  Neuropsychiatr Dis Treat       Date:  2019-09-13       Impact factor: 2.570

8.  Comparative Diagnostic Accuracy Of ACE-III And MoCA For Detecting Mild Cognitive Impairment: A Letter To The Editor [Letter].

Authors:  Ellen Richards; Olivia Knowles
Journal:  Neuropsychiatr Dis Treat       Date:  2019-09-30       Impact factor: 2.570

9.  Guideline-conform translation and cultural adaptation of the Addenbrooke's Cognitive Examination III into German.

Authors:  Björn Weiss; Julius J Grunow; Max Rosenthal; David Hilfrich; Rudolf Mörgeli; Bruno Neuner; Friedrich Borchers; Antje Kraft; Henning Krampe; Claudia Denke; Claudia D Spies
Journal:  Ger Med Sci       Date:  2020-04-06

10.  Cognitive Assessment Tools for Screening Older Adults With Low Levels of Education: A Critical Review.

Authors:  José Wagner Leonel Tavares-Júnior; Ana Célia Caetano de Souza; Gilberto Sousa Alves; Janine de Carvalho Bonfadini; José Ibiapina Siqueira-Neto; Pedro Braga-Neto
Journal:  Front Psychiatry       Date:  2019-12-13       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.